DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Dare Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.71−0.02 (-2.57%)
Close on Oct 19, 2026
- Market cap
- $10.51M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
71.3%
Operating margin
-1315.5%
Net margin
-1300.7%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +10429.4% | -53.1% | – | – | |
| Gross profit | +7406.1% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 177.6% | 7708.7% | 845.5% | |
| Return on assets | -1.7% | -365.5% | -49.1% | |
| Current ratio | 0.06 | 0.91 | 1.14 | |
| Interest coverage | -15.0× | – | – | |
| Capex to revenue | 69.8% | – | 37.4% | |
| Diluted shares | 0M | 3M | 11M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Dare Bioscience generated $101.07M from operations and spent $1.67M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$101.07M
Used
$1.67M
Capital expenditure$1.67M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1300.7%
×Asset turnover0.04×
×Equity multiplier-17.22×
=Return on equity, FY2025845.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1300.7% | 0.04× | -17.22× | 845.5% |
| FY2024 | -41430.9% | 0.00× | -3.92× | 73.3% |
| FY2023 | -1074.2% | 0.09× | 10.74× | -994.7% |
| FY2022 | -309.5% | 0.20× | 2.00× | -124.1% |
| FY2016 | -87.8% | 0.02× | -103.32× | 177.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$13.40M
- Cash generatingOperating cash flow above zero-$9.89M
- Return on assets improvedROA up on the prior year-19.0% → -60.6%
- Earnings backed by cashOperating cash flow above net income-$9.89M vs -$13.40M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.85 → 1.14
- No dilutionShare count did not rise8M → 11M
- Gross margin improvedGross margin up on the prior year100.00% → 71.29%
- More efficientAsset turnover rose0.00 → 0.05